Among patients allocated to intensive blood glucose control, metformin showed a greater effect than chlorpropamide, glibenclamide, or insulin for any diabetes-related endpoint (p = 0.0034), all-cause mortality (p = 0.021), and stroke (p = 0.032). The gene discussed is INS; the disease is Stroke.